NasdaqGS - Delayed Quote USD

HilleVax, Inc. (HLVX)

12.79 +0.77 (+6.41%)
At close: April 26 at 4:00 PM EDT
12.79 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
133,345.00
133,345.00
62,613.00
15,770.00
1,295.00
Operating Income
-133,345.00
-133,345.00
-62,613.00
-15,770.00
-1,295.00
Net Non Operating Interest Income Expense
7,314.00
7,314.00
461.00
-2,844.00
-29.00
Other Income Expense
2,465.00
2,465.00
-97,657.00
-83,794.00
-779.00
Pretax Income
-123,566.00
-123,566.00
-159,809.00
-102,408.00
-2,103.00
Net Income Common Stockholders
-123,566.00
-123,566.00
-159,809.00
-102,408.00
-2,103.00
Diluted NI Available to Com Stockholders
-123,566.00
-123,566.00
-159,809.00
-102,408.00
-2,103.00
Basic EPS
-3.04
--
-5.89
-6.29
-0.13
Diluted EPS
-3.04
--
-5.89
-6.29
-0.13
Basic Average Shares
40,598.48
--
27,147.31
16,291.32
16,291.32
Diluted Average Shares
40,598.48
--
27,147.31
16,291.32
16,291.32
Total Operating Income as Reported
-133,345.00
-133,345.00
-65,113.00
-53,426.00
-1,295.00
Total Expenses
133,345.00
133,345.00
62,613.00
15,770.00
1,295.00
Net Income from Continuing & Discontinued Operation
-123,566.00
-123,566.00
-159,809.00
-102,408.00
-2,103.00
Normalized Income
-123,566.00
-123,566.00
-113,734.00
-38,841.00
-2,103.00
Interest Income
9,706.00
9,706.00
3,875.00
--
--
Interest Expense
2,392.00
2,392.00
3,414.00
2,844.00
29.00
Net Interest Income
7,314.00
7,314.00
461.00
-2,844.00
-29.00
EBIT
-121,174.00
-121,174.00
-156,395.00
-99,564.00
-2,074.00
EBITDA
-119,018.00
-119,018.00
-155,247.00
-99,561.00
-2,074.00
Reconciled Depreciation
2,156.00
2,156.00
1,148.00
3.00
--
Net Income from Continuing Operation Net Minority Interest
-123,566.00
-123,566.00
-159,809.00
-102,408.00
-2,103.00
Total Unusual Items Excluding Goodwill
--
--
-46,075.00
-63,567.00
--
Total Unusual Items
--
--
-46,075.00
-63,567.00
--
Normalized EBITDA
-119,018.00
-119,018.00
-109,172.00
-35,994.00
-2,074.00
12/31/2020 - 4/29/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TRDA Entrada Therapeutics, Inc.
12.45
+0.73%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
 
ANRO Alto Neuroscience, Inc.
14.18
+0.35%
 
STTK Shattuck Labs, Inc.
10.59
+8.28%
 
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
 
VALN Valneva SE
7.64
+1.32%
 
LRMR Larimar Therapeutics, Inc.
6.44
+1.74%
 
ANAB AnaptysBio, Inc.
21.00
+11.29%
 
HOWL Werewolf Therapeutics, Inc.
6.75
+8.70%
 
688428.SS InnoCare Pharma Limited
8.32
+2.21%